SU2C affiliated researcher led study to find long-term remissions in leukemia - Stand Up To Cancer

News

SU2C affiliated researcher led study to find long-term remissions in leukemia

A pioneering immunotherapy approach to treatment of chronic lymphocytic leukemia (CLL), the most common form of leukemia in adults, has shown long-term beneficial effects in a clinical trial with patients whose disease was not controlled by other therapies, according to a paper published in
Science Translational Medicine. Carl H. June, MD, director of the Translational Research Program at Abramson Cancer Center of the University of Pennsylvania and a member of the Stand Up To Cancer (SU2C) Scientific Advisory Committee (SAC), was leader of the clinical trial team.

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.